Search Results

There are 6458 results for: content related to: Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen

  1. You have free access to this content
    Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches

    Journal of Internal Medicine

    Volume 272, Issue 2, August 2012, Pages: 144–157, R. Valenta, R. Campana, K. Marth and M. van Hage

    Article first published online : 25 JUL 2012, DOI: 10.1111/j.1365-2796.2012.02556.x

  2. You have free access to this content
    Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 775–783, R. Valenta, B. Linhart, I. Swoboda and V. Niederberger

    Article first published online : 26 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02565.x

  3. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model

    Allergy

    Volume 70, Issue 12, December 2015, Pages: 1559–1568, S. Siebeneicher, S. Reuter, A. Wangorsch, M. Krause, K. Foetisch, A. Heinz, S. Naito, A. Reuter, C. Taube, S. Vieths, S. Scheurer and M. Toda

    Article first published online : 25 SEP 2015, DOI: 10.1111/all.12732

  4. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1

    Clinical & Experimental Allergy

    Volume 34, Issue 1, January 2004, Pages: 115–122, V. Mahler, S. Vrtala, O. Kuss, T. L. Diepgen, R. Suck, O. Cromwell, H. Fiebig, A. Hartl, J. Thalhamer, G. Schuler, D. Kraft and R. Valenta

    Article first published online : 14 JAN 2004, DOI: 10.1111/j.1365-2222.2004.01857.x

  5. You have free access to this content
    Review article: From allergen genes to new forms of allergy diagnosis and treatment

    Allergy

    Volume 63, Issue 3, March 2008, Pages: 299–309, S. Vrtala

    Article first published online : 4 FEB 2008, DOI: 10.1111/j.1398-9995.2007.01609.x

  6. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination

    Clinical & Experimental Allergy

    Volume 34, Issue 10, October 2004, Pages: 1525–1533, M. Focke, B. Linhart, A. Hartl, U. Wiedermann, W. R. Sperr, P. Valent, J. Thalhamer, D. Kraft and R. Valenta

    Article first published online : 12 OCT 2004, DOI: 10.1111/j.1365-2222.2004.02081.x

  7. You have free access to this content
    The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice

    Allergy

    Volume 61, Issue 2, February 2006, Pages: 173–180, B. Winkler, K. Hufnagl, A. Spittler, M. Ploder, E. Kállay, S. Vrtala, R. Valenta, M. Kundi, H. Renz and U. Wiedermann

    Article first published online : 12 JAN 2006, DOI: 10.1111/j.1398-9995.2006.01014.x

  8. You have free access to this content
    Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber

    Allergy

    Volume 68, Issue 6, June 2013, Pages: 724–731, W. Meyer, A. Narkus, A. M. Salapatek and D. Häfner

    Article first published online : 27 APR 2013, DOI: 10.1111/all.12148

  9. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules

    Clinical & Experimental Allergy

    Volume 40, Issue 9, September 2010, Pages: 1346–1352, I. Pree, M. H. Shamji, I. Kimber, R. Valenta, S. R. Durham and V. Niederberger

    Article first published online : 28 JUN 2010, DOI: 10.1111/j.1365-2222.2010.03548.x

  10. You have free access to this content
    Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level

    European Journal of Immunology

    Volume 33, Issue 12, December 2003, Pages: 3303–3310, Barbara Bohle, Astrid Radakovics, Beatrice Jahn-Schmid, Karin Hoffmann-Sommergruber, Gottfried F. Fischer and Christof Ebner

    Article first published online : 3 NOV 2003, DOI: 10.1002/eji.200324321

  11. You have free access to this content
    A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation

    Allergy

    Volume 67, Issue 11, November 2012, Pages: 1375–1382, C. Kitzmüller, M. Wallner, S. Deifl, S. Mutschlechner, C. Walterskirchen, G. J. Zlabinger, F. Ferreira and B. Bohle

    Article first published online : 13 SEP 2012, DOI: 10.1111/all.12016

  12. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT)

    Clinical & Experimental Allergy

    Volume 29, Issue 7, July 1999, Pages: 896–904, VALENTA, LIDHOLM, NIEDERBERGER, HAYEK, KRAFT and GRÖNLUND

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2222.1999.00653.x

  13. You have free access to this content
    Phenylcoumaran benzylic ether and isoflavonoid reductases are a new class of cross-reactive allergens in birch pollen, fruits and vegetables

    European Journal of Biochemistry

    Volume 268, Issue 20, October 2001, Pages: 5310–5320, Fariba Karamloo, Andrea Wangorsch, Hiroyuki Kasahara, Laurence B. Davin, Dieter Haustein, Norman G. Lewis and Stefan Vieths

    Article first published online : 20 DEC 2001, DOI: 10.1046/j.0014-2956.2001.02463.x

  14. Successive multiple ionic polymer layer coated capillaries in the separation of proteins – Recombinant allergen variants as a case study

    ELECTROPHORESIS

    Volume 31, Issue 11, June 2010, Pages: 1805–1812, Martin Weinbauer and Hanno Stutz

    Article first published online : 26 MAY 2010, DOI: 10.1002/elps.201000077

  15. You have free access to this content
    Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a

    Allergy

    Volume 59, Issue 1, January 2004, Pages: 65–73, A. Hartl, R. Hochreiter, T. Stepanoska, F. Ferreira and J. Thalhamer

    Article first published online : 12 DEC 2003, DOI: 10.1046/j.1398-9995.2003.00335.x

  16. You have free access to this content
    Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction

    FEBS Letters

    Volume 465, Issue 1, January 07, 2000, Pages: 39–46, Stéphane Denépoux, Petra B. Eibensteiner, Peter Steinberger, Susanne Vrtala, Vincenzo Visco, Anne Weyer, Dietrich Kraft, Jacques Banchereau, Rudolf Valenta and Serge Lebecque

    Article first published online : 28 DEC 1999, DOI: 10.1016/S0014-5793(99)01703-2

  17. You have full text access to this OnlineOpen article
    Human IgE against the major allergen Bet v 1 – defining an epitope with limited cross-reactivity between different PR-10 family proteins

    Clinical & Experimental Allergy

    Volume 44, Issue 2, February 2014, Pages: 288–299, M. Levin, A. M. Davies, M. Liljekvist, F. Carlsson, H. J. Gould, B. J. Sutton and M. Ohlin

    Article first published online : 22 JAN 2014, DOI: 10.1111/cea.12230

  18. How far can we simplify in vitro diagnostics for Fagales tree pollen allergy? A study with three whole pollen extracts and purified natural and recombinant allergens

    Clinical & Experimental Allergy

    Volume 29, Issue 6, June 1999, Pages: 848–855, VAN REE, VAN LEEUWEN, AKKERDAAS and R. C. AALBERSE

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2222.1999.00521.x

  19. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population

    Clinical & Experimental Allergy

    Volume 30, Issue 8, August 2000, Pages: 1076–1084, Pauli, Purohit, Oster, De Blay, Vrtala, * Niederberger, Kraft and * Valenta *

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2222.2000.00869.x

  20. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis

    Clinical & Experimental Allergy

    Volume 32, Issue 10, October 2002, Pages: 1448–1453, M. Van Hage-Hamsten, E. Johansson, A. Roquet, C. Peterson, M. Andersson, L. Greiff, S. Vrtala, R. Valenta and R. Grönneberg

    Article first published online : 8 OCT 2002, DOI: 10.1046/j.1365-2745.2002.01495.x